Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day
Lyell Immunopharma (Nasdaq: LYEL), a clinical-stage T-cell reprogramming company, has announced its participation in the Goldman Sachs Cell Therapy Day on October 1. Lynn Seely, MD, Lyell's President & CEO, will be part of a panel discussion focusing on next-generation cell therapies in oncology at 11:50 a.m. ET.
The company, which is advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, will provide a webcast of the presentation through the Investors section of their website at www.lyell.com. A replay of the webcast will be available on the company's website following the presentation date.
Lyell Immunopharma (Nasdaq: LYEL), un'azienda in fase clinica di riprogrammazione delle cellule T, ha annunciato la propria partecipazione al Goldman Sachs Cell Therapy Day il 1 ottobre. Lynn Seely, MD, Presidente e CEO di Lyell, farà parte di una discussione panel incentrata sulle terapie cellulari di nuova generazione in oncologia alle 11:50 ora orientale.
L'azienda, che sta promuovendo un'ampia gamma di terapie cellulari per pazienti con tumori solidi o malattie ematologiche, offrirà un webcast della presentazione nella sezione Investitori del proprio sito web all'indirizzo www.lyell.com. Una replica del webcast sarà disponibile sul sito web dell'azienda dopo la data della presentazione.
Lyell Immunopharma (Nasdaq: LYEL), una empresa en etapa clínica de reprogramación de células T, ha anunciado su participación en el Día de Terapia Celular de Goldman Sachs el 1 de octubre. Lynn Seely, MD, Presidente y CEO de Lyell, formará parte de un panel de discusión centrado en las terapias celulares de nueva generación en oncología a las 11:50 a.m. ET.
La empresa, que avanza en un diverso pipeline de terapias celulares para pacientes con tumores sólidos o malignidades hematológicas, proporcionará un webcast de la presentación a través de la sección de Inversores de su sitio web en www.lyell.com. Una repetición del webcast estará disponible en el sitio web de la empresa después de la fecha de la presentación.
Lyell Immunopharma (Nasdaq: LYEL), 임상 단계의 T 세포 재프로그래밍 회사는 10월 1일에 골드만 삭스 세포 치료의 날에 참여한다고 발표했습니다. Lynn Seely, MD, Lyell의 사장 겸 CEO는 오전 11시 50분 동부 표준시의 온콜로지의 차세대 세포 치료법에 관한 패널 토론에 참여합니다.
이 회사는 고형 종양 또는 혈액 악성 종양 환자를 위한 다양한 세포 치료 파이프라인을 진행하고 있으며, www.lyell.com의 투자자 섹션을 통해 프레젠테이션의 웹캐스트를 제공할 예정입니다. 프레젠테이션 날짜 이후에는 회사 웹사이트에서 웹캐스트의 재생이 가능할 것입니다.
Lyell Immunopharma (Nasdaq: LYEL), une entreprise de reprogrammation des cellules T en phase clinique, a annoncé sa participation au Goldman Sachs Cell Therapy Day le 1er octobre. Lynn Seely, MD, Président et CEO de Lyell, participera à un panel de discussion axé sur les thérapies cellulaires de nouvelle génération en oncologie à 11h50 ET.
L'entreprise, qui avance dans un vaste portefeuille de thérapies cellulaires pour des patients atteints de tumeurs solides ou de maladies hématologiques, fournira un webcast de la présentation sur la section Investisseurs de son site internet à www.lyell.com. Un rediffusion du webcast sera disponible sur le site après la date de la présentation.
Lyell Immunopharma (Nasdaq: LYEL), ein Unternehmen in der klinischen Phase zur Reprogrammierung von T-Zellen, hat seine Teilnahme am Goldman Sachs Cell Therapy Day am 1. Oktober angekündigt. Lynn Seely, MD, Präsidentin und CEO von Lyell, wird Teil einer Podiumsdiskussion sein, die sich um zelluläre Therapien der nächsten Generation in der Onkologie dreht, und zwar um 11:50 Uhr ET.
Das Unternehmen, das ein vielfältiges Portfolio von Zelltherapien für Patienten mit soliden Tumoren oder hämatologischen Malignitäten vorantreibt, wird über die Investoren-Seite seiner Website unter www.lyell.com einen Webcast der Präsentation anbieten. Eine Wiederholung des Webcasts wird nach dem Präsentationstermin auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors or hematologic malignancies, announced today that Lynn Seely, MD, Lyell’s President & CEO, will participate on a panel discussion on next-generation cell therapies in oncology at Goldman Sachs Cell Therapy Day on October 1 at 11:50 a.m. ET.
A webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date.
About Lyell
Lyell is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies, including three product candidates in or entering Phase 1 clinical development for patients with solid tumors or hematologic malignancies. Lyell’s product candidates are enhanced with novel anti-exhaustion technology designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. Lyell applies its proprietary ex vivo genetic and epigenetic reprogramming technology to address these barriers to develop new medicines with improved durable clinical outcomes. Lyell is based in South San Francisco, California with facilities in Seattle and Bothell, Washington. To learn more, please visit www.lyell.com.
Contact:
Ellen Rose
Senior Vice President, Communications and Investor Relations
erose@lyell.com
FAQ
When is Lyell Immunopharma (LYEL) participating in the Goldman Sachs Cell Therapy Day?
Who will represent Lyell Immunopharma (LYEL) at the Goldman Sachs Cell Therapy Day?
What will be the focus of Lyell Immunopharma's (LYEL) panel discussion at the Goldman Sachs event?
How can investors access Lyell Immunopharma's (LYEL) presentation at the Goldman Sachs Cell Therapy Day?
